<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00830778</url>
  </required_header>
  <id_info>
    <org_study_id>S51480</org_study_id>
    <nct_id>NCT00830778</nct_id>
  </id_info>
  <brief_title>Reduced Pancreatic Fistula Rate Following Pancreaticoduodenectomy: Trial on Pancreaticogastrostomy Versus Pancreaticojejunostomy</brief_title>
  <official_title>Reduced Postoperative Pancreatic Fistula Rate Following Pancreaticoduodenectomy; Multicentric Randomized Controlled Trial on Pancreaticogastrostomy vs. Pancreaticojejunostomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baki Topal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Erasme ULB, Brussels</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jolimont, Brussels</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St.Lucas, Brugge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Hospital Groeninge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinique Saint Joseph, Liège</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jan Palfijn, Antwerp</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St.Jan, Brugge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Monica, Deurne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Gasthuisberg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The incidence of complications after pancreaticoduodenectomy (PD) is around 50 %. The&#xD;
      postoperative course after PD is strongly dependent of the occurrence of pancreatic fistula&#xD;
      (POPF), which determines postoperative mortality, length of hospital stay and costs. The&#xD;
      incidence of POPF after PD is dependent of its definition, and is reported in up to 20% of&#xD;
      patients.&#xD;
&#xD;
      There is disagreement on whether to perform a pancreaticojejunostomy (PJ) or a&#xD;
      pancreaticogastrostomy (PG) after PD. The aim of the current randomized controlled trial is&#xD;
      to study whether PG significantly reduces the rate of POPF following PD for pancreatic or&#xD;
      peri-ampullary tumours. Secondary endpoints are the reduction of overall postoperative&#xD;
      complication rate and their severity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Therapeutic intervention&#xD;
&#xD;
        -  Surgeons who have performed a minimum of five (5) PG and PJ procedures can include&#xD;
           patients in this randomized trial.&#xD;
&#xD;
        -  Any dissection device or technique is allowed.&#xD;
&#xD;
        -  Pancreatic anastomosis (PG or PJ)&#xD;
&#xD;
             -  1-layer or 2-layer anastomosis is allowed but has to be registered&#xD;
&#xD;
             -  mono-filament and/or poly-filament suture material is allowed but has to be&#xD;
                registered&#xD;
&#xD;
             -  no pancreatic stent will be placed&#xD;
&#xD;
        -  Drainage: one (1) or more closed drain(s) with or without suction is allowed in the&#xD;
           vicinity of the pancreatic anastomosis&#xD;
&#xD;
        -  Enteral tube feeding (tube positioned in the jejunum at the time of surgery, and distal&#xD;
           to the pancreatic anastomosis) as well as total parenteral nutrition (TPN) is allowed&#xD;
&#xD;
        -  Gastrostomy tube (percutaneous) is allowed&#xD;
&#xD;
        -  Somatostatin: start intra-operatively and administered for seven (7) days after surgery&#xD;
           at a dose of 6 mg/d&#xD;
&#xD;
        -  Prophylactic use of antibiotics during 24h post-operatively&#xD;
&#xD;
        -  Prophylactic use of Ranitidine as well as any PPI (proton pump inhibitor) is allowed to&#xD;
           prevent peptic ulcer&#xD;
&#xD;
      Clinical evaluation and assessment criteria&#xD;
&#xD;
        -  The number and type of POPF will be recorded according to the ISGPF guidelines and based&#xD;
           on findings on day 3 (three) after surgery&#xD;
&#xD;
        -  The number and type of postoperative complications will be recorded. The&#xD;
           therapy-oriented severity grading system (TOSGS) of complications will be used and&#xD;
           complications will be allocated to surgical (SSC) and non-surgical site (NSSC)&#xD;
           complications&#xD;
&#xD;
        -  The adequacy of the surgical resection margins (pR0) and the magnitude of the&#xD;
           tumour-free resection margin (millimetres) will be monitored&#xD;
&#xD;
        -  Postoperative length of hospital stay (LOS) will be registered&#xD;
&#xD;
      Patient randomization and registration procedure (randomization lists attached)&#xD;
&#xD;
        -  This is a multicentric randomized controlled trial.&#xD;
&#xD;
        -  Patient randomization will be done intra-operatively since a substantial number of&#xD;
           patients could be dropped out intra-operatively because of the presence of unexpected&#xD;
           intra-abdominal metastases at the time of surgery.&#xD;
&#xD;
        -  Patient stratification will be performed for each centre and will be based on the&#xD;
           diameter of the pancreatic duct. A pancreatic duct at the level of the surgical&#xD;
           transsection margin measuring 3 millimetres or less in diameter is defined as being a&#xD;
           &quot;soft pancreas&quot;. A pancreatic duct measuring more than 3 millimetres is defined as a&#xD;
           &quot;hard pancreas&quot;.&#xD;
&#xD;
        -  A prospective registration of following parameters will be performed: intra-operative&#xD;
           diameter of the pancreatic duct at the surgical transection margin, diameter of the&#xD;
           pancreas at the surgical transection margin, pancreatic tissue consistency assessed by&#xD;
           the surgeon: soft vs. hard, post-operative pathology parameters.&#xD;
&#xD;
      Statistical analysis and sample size calculation based on a stratified design&#xD;
&#xD;
        -  40% of patients are expected to have a hard pancreas and 60% a soft pancreas.&#xD;
&#xD;
        -  It is assumed that the magnitude of the effect of the intervention (PJ vs. PG) on the&#xD;
           POPF rate, expressed as an odds ratio (OR), is similar in both strata.&#xD;
&#xD;
        -  The needed sample size is calculated to have 80% power to detect a common odds ratio of&#xD;
           2.7. POPF rates of 12% and 20% are assumed after PJ within the hard and soft pancreas&#xD;
           stratum respectively (yielding 4.8% and 8.4% after PG). Note that, given the unequal&#xD;
           size strata, this leads to an expected POPF rate of 16.8% after PJ and 7% after PG (≈12%&#xD;
           POPF overall).&#xD;
&#xD;
        -  A 2-sided (with alpha=5%) Mantel-Haenszel test of OR=1 for stratified 2x2 tables is&#xD;
           planned&#xD;
&#xD;
        -  168 patients are required per group (total patient population 336)&#xD;
&#xD;
        -  Expected duration of recruitment: 3-4 years&#xD;
&#xD;
        -  An interim analysis will be performed annually (i.e. after inclusion of 1/3 and 2/3 of&#xD;
           the patients) to to allow early stop of the study (or accrual of patients in a specific&#xD;
           treatment group) due to rejection of the null hypothesis. Using the O'Brien-Fleming&#xD;
           method (O'Brien and Fleming 1979) results in respectively |3.471|, |2.454| and |2.004|&#xD;
           as critical values for the Z-statistic at the three analysis moments. Otherwise stated,&#xD;
           p-values are declared significant if &lt;.00052, &lt;0.0141 and &lt;0.0451 at respectively the&#xD;
           first interim analysis, the second interim analysis and at the final analysis.&#xD;
&#xD;
        -  Exact 95% confidence intervals will be calculated for the POPF and post-operative&#xD;
           complication rates within each stratum. A stratified Mann-Whitney U test will be used&#xD;
           for the TOSGS grading.&#xD;
&#xD;
      Translational research: optional Prognostic relevance of gene expression profiling in&#xD;
      pancreatic cancer: analyses will be performed at UZ.Leuven/KU.Leuven (project coordinator&#xD;
      B.Topal)&#xD;
&#xD;
        -  Fresh tissue samples from pancreatic cancer and from non-tumoral pancreatic tissue will&#xD;
           be stored in RNA-later (samples in 2 separate tubes; 5-10 volumes of RNA-later)&#xD;
&#xD;
        -  Sample tubes will be transported (or picked up by the coördinator's research team),&#xD;
           within 3 days from sampling, to be stored in -80°C for further analyses&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of clinical postoperative pancreatic fistula (POPF) rate</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of overall postoperative pancreatic fistula rate</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of the severity of postoperative complications</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">336</enrollment>
  <condition>Tumors</condition>
  <arm_group>
    <arm_group_label>PG anastomosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pancreaticogastrostomy (PG) reconstruction/anastomosis after pancreaticoduodenectomy (PD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PJ anastomosis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pancreaticojejunostomy (PJ) reconstruction/anastomosis after pancreaticoduodenectomy (PD)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pancreaticojejunostomy</intervention_name>
    <description>Pancreaticojejunostomy (PJ) reconstruction/anastomosis</description>
    <arm_group_label>PJ anastomosis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pancreaticogastrostomy</intervention_name>
    <description>Pancreaticogastrostomy (PG) reconstruction/anastomosis</description>
    <arm_group_label>PG anastomosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients, male or female, who undergo PD for a pancreatic or peri-ampullary tumor&#xD;
&#xD;
          -  Age between 18 to 85 years&#xD;
&#xD;
          -  Patients with and without pre-operative biliary drainage (for obstructive jaundice)&#xD;
&#xD;
          -  Concomitant surgical procedures such as simultaneous colonic resection etc.&#xD;
&#xD;
          -  Reconstruction of the portal vein or superior mesenteric vein&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18years&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Pre-operative radiotherapy&#xD;
&#xD;
          -  PD for IPMT&#xD;
&#xD;
          -  PD for chronic pancreatitis&#xD;
&#xD;
          -  PD for pancreatic trauma&#xD;
&#xD;
          -  PD for post-ERCP complications&#xD;
&#xD;
          -  Any arterial reconstruction at the time of surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Baki Topal, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Universitaire Ziekenhuizen Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claude Bertrand, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Jolimont, Brussels</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean Closset, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Erasme (ULB), Brussels</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Henk Thieren, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AZ. St.Lucas, Brugge</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Franky Vansteenkiste, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>General Hospital Groeninge</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Francois Gigot, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université Catholique de Louvain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph Weerts, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St.Joseph Hospital, Liège</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Geert Roeyen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Antwerp, Antwerp</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc Janssens, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>J.Palfijn Hospital, Antwerp</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tom Feryn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St.Jan Hospital, Brugge</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven Pauli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Monica Hospital, Deurne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>January 27, 2009</study_first_submitted>
  <study_first_submitted_qc>January 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2009</study_first_posted>
  <last_update_submitted>September 11, 2012</last_update_submitted>
  <last_update_submitted_qc>September 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gasthuisberg</investigator_affiliation>
    <investigator_full_name>Baki Topal</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>pancreas</keyword>
  <keyword>surgery</keyword>
  <keyword>cancer</keyword>
  <keyword>pancreaticoduodenectomy (PD)</keyword>
  <keyword>peri-ampullary tumours (ampulla, duodenum, distal bile duct, and miscellaneous tumours)</keyword>
  <keyword>pancreatic tumors</keyword>
  <keyword>peri-ampullary tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Fistula</mesh_term>
    <mesh_term>Fistula</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

